

Remarks


In response to the Restriction Requirement mailed April 24, 2006, the applicants hereby elect Group II, namely the combination of an anti-tumor antibody and a cytokine used in the treatment of cancer, wherein the cytokine is an interferon. In further response to the election of species requirement, the applicants hereby elect the administration of the cytokine in a substantially constant dose during treatment.

The Restriction Requirement is traversed, as the present claims have been restricted to the use of an antibody which is directed against the MN antigen. Support for the limitation of the antibody will be found in claim 13 and the specification, for instance, at page 6, lines 20-25. The treatment of tumors with a combination of a cytokine and an antibody directed against the MN antigen constitutes a special technical feature which defines a contribution over the prior art. Accordingly, reconsideration and withdrawal of the Restriction Requirement is believed in order.

Early and favorable action on the merits is awaited.

Respectfully submitted,

By



Robert B. Murray
Attorney for Applicant
Registration No. 22,980
ROTHWELL, FIGG, ERNST & MANBECK
1425 K. Street, Suite 800
Washington, D.C. 20005
Telephone: (202) 783-6040

RBM/cb